Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:PAVMNASDAQ:PETVNASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$0.16-7.6%$0.19$0.17▼$2.93$3.43M0.513.36 million shs486,122 shsPAVMPAVmed$0.75-2.0%$0.71$0.55▼$2.43$12.90M1.13115,087 shs81,835 shsPETVPetVivo$0.52+0.2%$0.55$0.29▼$0.98$12.59M1.8521,210 shs16,713 shsPSTVPlus Therapeutics$0.84-14.3%$0.93$0.24▼$2.67$14.33M0.684.23 million shs2.19 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell-7.55%+3.02%-2.24%-63.68%-91.84%PAVMPAVmed-1.99%+6.30%-0.63%+16.47%-59.21%PETVPetVivo+0.19%-6.44%+5.39%-27.11%-34.04%PSTVPlus Therapeutics-14.32%+27.95%-41.07%-31.49%-47.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/APAVMPAVmed4.1342 of 5 stars3.83.00.04.33.30.80.6PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics1.7442 of 5 stars3.52.00.00.02.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/APAVMPAVmed 3.50Strong Buy$19.502,483.81% UpsidePETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 3.00Buy$11.501,264.66% UpsideCurrent Analyst Ratings BreakdownLatest CTCX, PETV, PSTV, and PAVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.504/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/17/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$9.00 ➝ $9.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K104.40N/AN/A$1.07 per share0.15PAVMPAVmed$3.00M4.31N/AN/A($3.35) per share-0.23PETVPetVivo$1.05M12.04N/AN/A($0.03) per share-17.33PSTVPlus Therapeutics$4.91M2.92N/AN/A($0.30) per share-2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/APAVMPAVmed-$64.18M-$2.25N/AN/AN/A602.97%N/A-92.36%5/12/2025 (Estimated)PETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)PSTVPlus Therapeutics-$13.32M-$2.50N/AN/AN/A-225.07%N/A-154.56%5/13/2025 (Estimated)Latest CTCX, PETV, PSTV, and PAVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PSTVPlus Therapeutics-$0.24N/AN/AN/AN/AN/A5/12/2025Q1 2025PAVMPAVmed-$0.40N/AN/AN/A$0.02 millionN/A3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29PAVMPAVmedN/A0.060.06PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A0.440.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%PAVMPAVmed19.93%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%PAVMPAVmed11.30%PETVPetVivo10.84%PSTVPlus Therapeutics5.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionablePETVPetVivo2024.22 million19.06 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableCTCX, PETV, PSTV, and PAVM HeadlinesRecent News About These CompaniesPlus Therapeutics appoints Kyle Guse to board of directorsApril 23 at 8:57 PM | markets.businessinsider.com5 Small Drug Stocks to Buy as Tariff-Related Uncertainty LoomsApril 23 at 10:35 AM | zacks.comPlus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of DirectorsApril 23 at 8:00 AM | globenewswire.comAscendiant Capital Markets Boosts Plus Therapeutics (NASDAQ:PSTV) Price Target to $20.00April 22 at 2:47 AM | americanbankingnews.comPlus Therapeutics Appoints Kyle Guse to BoardApril 18, 2025 | tipranks.comPlus Therapeutics presents data highlighting clinical benefit, safety of REYOBIQApril 16, 2025 | markets.businessinsider.comPlus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal MetastasesApril 15, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's What You Should KnowApril 1, 2025 | zacks.comPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comPlus Therapeutics price target lowered to $5.50 from $8 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comWhy Plus Therapeutics, Inc.’s (PSTV) Stock Is Down 23.03%March 29, 2025 | aaii.comPlus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timelineMarch 28, 2025 | msn.comPlus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comPlus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue EstimatesMarch 27, 2025 | zacks.comPlus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comWhy Plus Therapeutics Is Rising In Pre-market?March 22, 2025 | nasdaq.comPSTV Stock Surges as FDA Accepts Proprietary Name for Lead DrugMarch 21, 2025 | zacks.comPlus Therapeutics announces FDA conditionally accepted name REYOBIQMarch 21, 2025 | markets.businessinsider.comWhy Plus Therapeutics Inc. (PSTV) Surged On Thursday?March 21, 2025 | msn.comPlus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug CandidateMarch 20, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTCX, PETV, PSTV, and PAVM Company DescriptionsCarmell NASDAQ:CTCX$0.16 -0.01 (-7.55%) As of 04/23/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.PAVmed NASDAQ:PAVM$0.75 -0.02 (-1.99%) As of 04/24/2025 04:00 PM EasternPAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.PetVivo NASDAQ:PETV$0.52 +0.00 (+0.19%) As of 04/24/2025 02:48 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.84 -0.14 (-14.32%) As of 04/24/2025 04:00 PM EasternPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
